



# 2024 Winter Symposium and Reception

**Friday, December 6, 2024, 6:00 pm – 10:00 pm**

University Club Atop Symphony Tower • 750 B St Suite #3400 • San Diego, CA 92101





  
**Verzenio**<sup>®</sup>  
abemaciclib  
50 | 100 | 150 | 200 mg tablets

**FIND THE SUPPORT  
YOUR PATIENTS NEED  
WITH VERZENIO**

Access resources at  
[Verzenio.com](https://www.verzenio.com)





## 2024 Corporate Partners

---



## 2024 Annual Hematology Supporters

---



### Bronze Sponsor

---



### Exhibitors

---



# NOW APPROVED for a new indication



Patient  
portrayal.

# available today



There's more to discover at  
[KISQALI-HCP.COM](https://www.kisqali-hcp.com)



## CONTENTS

Event Sponsors . . . . .	page 1
About CAHON . . . . .	page 3
Upcoming CAHON Events . . . . .	page 5
Meeting Agenda . . . . .	page 6
CAHON Young Investigator Awards . . . . .	page 7
About Our Speakers . . . . .	page 8

## ABOUT CAHON

Founded by Chinese American Hematologists and Oncologists in 2005, the primary missions of CAHON are to foster communications amongst Chinese American medical professionals for the delivery of high-quality health care to patients with neoplastic and hematological diseases, and to promote medical information exchange between the United States and China in the field of hematology and oncology. CAHON strives to serve as a bridge among its members and between Chinese and American Hematology-Oncology communities for medical and educational exchange.



## THE STORY BEHIND THE LOGO

CAHON'S logo was designed by Drs. Weijing Sun, Ke Liu, and Jeffrey Ye, under the supervision of the CAHON Board. The design has the following elements and takes the following considerations:

- The overall shape represents the globe.
- The blue, white, red and yellow represent the colors of two nations' flags. China and the US.
- The yellow and red stripes above the blue represent bridges. One of CAHON's key missions is to serve as a bridge between Chinese American Hematology-Oncology communities for medical and educational exchange.
- The white space is in the shape of a heart. The hearts of our members continue to drive our mission to provide high quality patient care to everyone.

## CAHON MEMBERSHIP

Apply to become a CAHON Member at [cahon.org](http://cahon.org)

### Value of a CAHON Membership

By joining CAHON you will have access to:

- A growing network of Chinese American professionals working in your field
- A private WeChat group where you can submit clinical questions to respected colleagues who are knowledgeable in specific areas of hematology and oncology
- Reduced or waived registration fees for all CAHON events and meetings along with priority hotel reservations
- Members-only section of the CAHON website featuring the member directory; and
- Travel award opportunities

## MEMBERSHIP CATEGORIES

Regular/Active Membership

Associate Membership

Allied Membership

Visit [cahon.org/membership](http://cahon.org/membership) for more information on membership.





Committed to discovering, developing, and providing novel therapies that significantly improve the lives of patients



[www.TAVALISSEhcp.com](http://www.TAVALISSEhcp.com)



[www.GAVRETO-hcp.com](http://www.GAVRETO-hcp.com)



[www.REZLIDHIAhcp.com](http://www.REZLIDHIAhcp.com)

Please see Full Prescribing Information, including Boxed Warning, at the Rigel exhibit.

RIGL\_FRN-24044 0924



SARCLISA + VRd is

**NOW APPROVED**

Discover the data from the IMROZ trial at [sarclisahcp.com](http://sarclisahcp.com)



VRd-bortezomib, lenalidomide, and dexamethasone.

**sanofi**

©2024 Sanofi. All rights reserved. SARCLISA and Sanofi are registered trademarks of Sanofi or an affiliate. MAT-US-2410885-v1.0-11/2024



# Save the Dates!

---

## COMMUNITY ONCOLOGY FORUM (COF)

**Saturday, March 29, 2025**  
**MGM National Harbor**  
**Oxon Hill, MD**

CAHON's Community Oncology Forum is a one-day program that is geared towards practicing oncologists/hematologists. The target audiences are clinicians, clinical fellows, and health care related specialists working the related areas. The COF will offer expert perspectives and practical insights into the use of immunotherapy and targeted treatments in cancer care. This event also helps to foster collaboration and provides a forum for interaction and collaboration between practicing hematologists and oncologists working in the field.

## SUMMER SYMPOSIUM AND RECEPTION

**Saturday, May 31, 2025**  
**The Metropolitan Club at Willis Tower**  
**Chicago, IL**

Held in conjunction with ASCO, the Summer Symposium will offer expert perspectives and practical insights on current advancements in a variety of cancer treatments, as well as foster collaboration and provide a forum for interaction and collaboration between hematologists and oncologists.

## 12<sup>TH</sup> ANNUAL NEW YORK ONCOLOGY FORUM (NYOF)

**October 4-5, 2025**  
**Sheraton LaGuardia East**  
**Flushing, NY**

The CAHON annual New York Oncology Forum (NYOF) is a one-and-a-half-day educational program that includes presentations on new developments and updates from the latest ASH, ASCO and SITC meetings including novel agents for Hematology and Oncology. This annual event draws more than 100 clinicians, researchers, medical students, clinical fellows as well as laboratory and health care related scientists working in hematology and oncology.

## WINTER SYMPOSIUM AND RECEPTION

**December 2025**  
**Location to Be Determined**

Held in conjunction with ASH, the Winter Symposium will offer expert perspectives and practical insights on current advancements in a variety of cancer treatments, as well as foster collaboration and provide a forum for interaction and collaboration between hematologists and oncologists.



# Session Agenda

---

<b>6:00 – 7:00 pm</b>	<b>Doors and Registration Open, Social Gathering, Visit Exhibit Booths</b>
<b>7:00 – 7:30 pm</b>	<b>CAHON PRESENTATIONS</b>  <b>Opening Remarks and Introduction of VIP Guests</b> Jing-Zhou Hou, MD, PhD – <i>CAHON Board Chair, University of Pittsburgh Medical Center</i>  <b>CAHON Updates</b> Liang Deng, MD, PhD – <i>CAHON President, Memorial Sloan Kettering Cancer Center</i>  <b>Updates on CAHON Journals</b> Delong Liu, MD, PhD – <i>Editor-in-Chief, Journal of Hematology &amp; Oncology, New York Medical College</i>
<b>7:30 – 8:20 pm</b>	<b>SCIENTIFIC PRESENTATIONS</b>
<b>7:30 – 7:50</b>	<b>Wanderings Between GVHD and GVL: A 25 Year Saga</b> Speaker: Robert Negrin, MD – <i>Stanford University</i>
<b>7:50 – 8:05</b>	<b>NHL in China</b> Speaker: Yuqin Song, MD, PhD – <i>Peking University Cancer Hospital</i>
<b>8:05 – 8:20</b>	<b>Future of Myeloma Care</b> Speaker: Brian G.M. Durie, MD – <i>International Myeloma Foundation Founder and Board Chairman Emeritus</i>
<b>8:20 – 8:35 pm</b>	<b>Young Investigator Award Ceremony</b> Presented by the CAHON Academic Committee
<b>8:35 – 8:40 pm</b>	<b>Closing Remarks</b> Jing-Zhou Hou, MD, PhD – <i>CAHON Board Chair, University of Pittsburgh Medical Center</i>
<b>8:40 – 10:00pm</b>	<b>Social Gathering</b>
<b>8:40 – 9:10</b>	<b>Career Development Mentoring Session</b> Open to all fellows and residents. Meet with Senior CAHON members to discuss career development in academia, clinical practice, industry and government.
<b>10:00 pm</b>	<b>Conclude</b>

\*Food and drinks will be provided throughout the symposium

## Meeting Organizers

JingZhou Hou, MD, PhD – *Chair, CAHON Board Chair, University of Pittsburgh Medical Center*  
Liang Deng, MD, PhD – *Co-Chair, CAHON President, Memorial Sloan Kettering Cancer Center*  
Hongtao Liu, MD, PhD – *University of Wisconsin at Madison*  
Yucai Wang, MD, PhD – *Mayo Clinic*  
J. Christine Ye, MD, MS – *MD Anderson Cancer Center*  
Hong Zheng, MD, PhD – *Penn State Hershey Cancer Institute*



## YIA Award Winners

---



### **Cho Han Chiang, MD**

Dr. Cho Han Chiang is a third-year resident at Mount Auburn Hospital/Harvard Medical School. He completed his medical training at the National Taiwan University College of Medicine and later earned a master's degree in clinical investigation at Harvard Medical School. His research focuses on improving cancer therapy-related cardiotoxicity and cancer-associated thrombosis, with a broader goal of improving patient outcomes through clinical outcomes research using large datasets. Dr. Chiang has contributed significantly to this field with over 50 publications.



### **Jun Liu, MD, PhD**

Dr. Jun Liu is a physician-scientist with PhD in developmental biology from University of Cambridge (UK) and MD from Harvard Medical School. She completed training in clinical pathology and recently completed transfusion medicine fellowship training in the transfusion medicine fellowship at the Harvard combined transfusion medicine fellowship program (2023-2024). She joined the faculty at Brigham and Women's Hospital while working as a research fellow in the laboratory of Dr Li Chai. She is passionate about research in translational hematology/oncology and diagnostics innovation and has spearheaded several projects developing new therapies for hemoglobinopathies.



### **James Wu, MD**

Dr. James Wu is a first-year hematology/oncology fellow at the Medical College of Wisconsin in Milwaukee, Wisconsin. He is part of the Medical College of Wisconsin Physician Scientist Immersion Program, funded through an R38 grant through the National Heart, Lung, and Blood Institute. His passions include cancer health disparities and global health research with a specific interest in Asian populations.



### **Xia (Yaya) Wu, MD**

Dr. Xia Wu is a graduate of Peking Union Medical College and is currently a third-year Internal Medicine resident at Tufts Medical Center. Her research interests include, but are not limited to, clinical and translational research in multiple myeloma and AL amyloidosis. She plans to apply for a hematology/oncology fellowship in 2025 and hopes to continue her career in the field.



### **Yuan Yao, MD, MS**

Dr. Yuan Yao is a first-year hematology/oncology fellow at Mayo Clinic in Rochester, MN. Born and raised in Tianjin, China, Yuan completed her undergraduate and medical education at Tsinghua University in Beijing and earned a Master of Research from the University of Melbourne in Australia. Yuan's clinical and research interests lie in malignant hematology, with current projects focusing on genetic predispositions and clinical outcomes in chronic lymphocytic leukemia and its precursor, monoclonal B-cell lymphocytosis.



### **Yumang Zhang, MD**

Dr. Yumeng Zhang is an Assistant Professor in the Department of Oncologic Sciences at the University of South Florida and an Assistant Member in the Department of Malignant Hematology at Moffitt Cancer Center. Her research focuses on developing immune-based therapies for T-cell lymphomas and improving diversity in clinical trials. She is passionate about enhancing healthcare access for Asian American communities and advancing personalized treatments for lymphoma patients through innovative clinical trial designs.

**THE WINTER 2024 YOUNG INVESTIGATOR AWARDS (YIA) ARE SPONSORED BY**



## Speakers



**Robert Negrin** – Robert Negrin, MD – Dr. Robert Negrin is a professor of medicine and former Chief of the Division of Blood and Marrow Transplantation at Stanford University. He received his undergraduate degree from the University of California at Berkeley and MD from Harvard Medical School. He trained in Internal Medicine and Hematology at Stanford. He joined the faculty at Stanford University in 1990 and was promoted to Professor in 2004.

His research focuses on developing a more fundamental understanding of graft vs host and graft vs tumor reactions with a particular interest in immune regulatory mechanisms. Several of the concepts developed in his laboratory have been translated to clinical studies both as investigator-initiated trials and in collaboration with industrial partners. He has published over 290 manuscripts and 43 book chapters. He has won a number of awards including fellowships from the Damon Runyon Walter Winchell Cancer Fund and the Jose Carreras International Leukemia Foundation. He was a recipient of a Distinguished Clinical Science Award from the Doris Duke Foundation. He is an elected member of the Association of American Physicians.

Dr. Negrin has served on multiple editorial boards and was an Associate Editor of Blood and the Founding Editor in Chief at Blood Advances. He has served as the President of the International Society of Cellular Therapy and the American Society of Blood and Marrow Transplantation (currently American Society of Transplantation and Cellular Therapy). He was elected Vice President of the American Society of Hematology and will serve successive terms as President-Elect (2024-2025) and President (2025-2026).



**Yuqin Song, MD, PhD** – Dr. Yuqin Song is a Professor of Medical Oncology/Hematology, Deputy Director of Lymphoma Department, Vice President of Peking University Cancer Hospital & Beijing Cancer Research Institute. Dr. Song oversees the GCP office, Ethics Committee, basic research and translational

research. She holds a MD in Hematology from Shandong University and a PhD in Oncology from Peking University Health Science Center

Dr. Song specializes in the clinical diagnosis and treatment of lymphoma. Her work focuses on clinical trials of novel agents and cellular therapies, such as novel BTK inhibitors, PI3K inhibitors, PD-1 antibodies, CAR T cells in different kinds of lymphoma subtypes. She is the Leading PI or co-leading PI of more 100 clinical trials in lymphoma, such as Zanubrutinib approved by CDE and FDA, and Relma-cel by CDE in China.

Her research interests include BTK inhibitor resistance and preclinical research of novel agents. Dr. Song's research was supported by projects from the National Science Foundation Committee and the Beijing government. She has published more than 70 research articles as first author or corresponding author in Annals of Oncology, Lancet Oncology, BLOOD, Lancet Hematology, JHO, Leukemia, CCR, et al.

Dr. Song is a member of the General secretary of Union for China Lymphoma Investigators (UCLI). She serves as Chairman of Hematology Division of Beijing Anti-cancer Association and Chairman of the Lymphoma Committee of China Human Health Promotion Association.



**Brian G.M. Durie, MD** – Dr. Brian G.M. Durie is a co-founder and board member of the International Myeloma Foundation, and a Hematologist/Oncologist specializing in multiple myeloma and related disorders at the Cedars-Sinai Medical Center in Los Angeles.

He was former Medical Director of Myeloma Research for the Academic Myeloma Consortium and co-chairman of the myeloma committee for the SWOG Cancer Research Network. Previously, he was a professor at the University of Arizona, College of Medicine, and the Charing Cross and Westminster School of Medicine at the University of London.

Dr. Durie is known for his notable research on multiple myeloma and blood disorders, most especially for developing the Durie-Salmon Staging System which continues to be used worldwide for clinically staging myeloma.

One of his key BSRI® projects, iStopMM (Iceland Screens, Treats, or Prevents Multiple Myeloma) is the first large-scale screening study in the field of myeloma aimed at preventing myeloma before it develops. His other key projects include the i2TEAMM (International Independent Team for Endpoint Approval of Myeloma MRD) Initiative and the BSRI® ASCENT Cure Trial.

Dr. Durie has received numerous accolades for his outstanding contributions in the field of myeloma: an Honorary Doctor of Medicine award from the Vrije Universiteit Brussel in 2019, the Waldenström's Award in 2009, and the Robert A. Kyle Lifetime Achievement Award in 2006. He is also a Leukemia Society of America Scholar and a U.S. Hematologic Research Foundation Annual Awardee.

He has written over 700 research papers, 16 book chapters, and 5 books. He also holds an international patent for scintillation autoradiography.

Dr. Durie is actively involved in global congress events in Europe, which include the annual Heidelberg Myeloma Workshop and annual conferences hosted by the Eurasian Hematology-Oncology Group.

He has produced over 200 videos for his weekly series, "Ask Dr. Durie," where he addressed patient questions about multiple myeloma and provides information on the latest developments in myeloma treatments. Complementing the video series was his weekly blog, where he also featured highlights of annual events including the ASH Educational Program, IMWG Summit, AMN Summit, GMAN Summit, and the Support Group Leaders Summit.

Dr. Durie hosted hundreds of IMF Patient & Family Webinars and Regional Community Workshops, providing up-to-date and direct information from leading myeloma experts to myeloma patients and their families.

Born in Scotland, Dr. Durie received his medical degree from the University of Edinburgh Medical School. He completed residencies and fellowships at Mayo Clinic and the University of Minnesota. He is board certified by the American Board of Internal Medicine with subspecialties in both medical oncology and hematology.



APPROVED ACROSS 5 INDICATIONS




# EVEN MORE PATIENTS MAY BE RIGHT FOR BRUKINSA



SEE THE DATA SUPPORTING  
APPROVAL ACROSS 5 INDICATIONS

BRUKINSA and BeiGene are registered trademarks  
owned by BeiGene, Ltd. or its affiliates.  
© BeiGene, Ltd. 2024 All Rights Reserved.  
0522-BRU-PRC-038-r1 3/2024



## Visit the Exelixis Exhibit

Booth Number: 3



SCAN TO DISCOVER MORE

EXELIXIS®  
©2024 Exelixis, Inc.

CABOMETYXhcp.com

CA-3428 09/24



**Chinese American Hematologist and Oncologist Network (CAHON)**

555 East Wells Street, Suite 1100 • Milwaukee, WI 53202 USA

Phone: 1 414-918-9890 • Fax: 1 414-276-3349

[www.cahon.org](http://www.cahon.org)